Based on its current operating plans, Xilio (XLO) anticipates that its existing cash and cash equivalents as of March 31, 2024, together with the $30.0 million upfront payment received in April 2024 under the license agreement with Gilead (GILD) and approximately $14.6 million in aggregate gross proceeds received in April 2024 from private placements with certain existing investors and Gilead, will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XLO:
- Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
- Xilio Therapeutics files to sell 17.58M shares of common stock for holders
- Fly Insider: Xilio, Aerovate among weekâs notable insider trades
- Xilio Therapeutics reports Q4 EPS (64c), consensus (64c)
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results